Alx Oncology Holdings Inc's Comment on Sales, Marketing and Customers
The company currently has no products on the market but expects its operations to be governed by various U.S. federal and state healthcare laws and regulations. Its customers include healthcare providers, prescribers, consultants, third-party payors, physicians, and other parties involved in the recommendation, prescription, marketing, sale, and distribution of its products. The company may also be subject to patient data privacy and security regulations, as well as additional healthcare statutory and regulatory requirements in foreign jurisdictions where it operates.
In an era where precision medicine is at the forefront of oncological research, ALX Oncology Holdings Inc. has taken a significant stride with its latest findings set to be presented at the highly anticipated San Antonio Breast Cancer Symposium (SABCS) 2024. The company will unveil new data from a Phase 1b/2 clinical trial that investigates the efficacy of evorpacept, a novel investigational CD47 blocker, paired with zanidatamab, an innovative dual HER2-targeted bispecific antibody. This combination therapy is aimed at patients grappling with advanced breast cancers, marking a potential breakthrough in treatment options.The trial highlights the synergy between the two agents evorpacept, designed to inhibit t...
In a promising development for multiple myeloma treatment, ALX Oncology has announced the dosing of the first patients in its UMBRELLA study, a randomized Phase 1/2 clinical trial evaluating the efficacy of Evorpacept, an investigational CD47-blocking therapeutic, in combination with Sarclisa, Sanofi s approved CD38 monoclonal antibody. This study aims to explore the synergistic potential of targeting both the CD47 and CD38 pathways, which are critical in myeloma pathogenesis and immune evasion. The UMBRELLA Study Design and s The UMBRELLA study is designed to assess the safety and effectiveness of this novel combination therapy in patients with multiple myeloma, a hematologic malignancy characterized by the...
: Recent clinical trial data from ALX Oncology Holdings Inc. has illuminated the potential of evorpacept, a next-generation CD47 blocker, in treating various forms of cancer. This article outlines the findings from three distinct clinical studies involving HER2-positive gastric cancer, human papillomavirus-mediated oropharyngeal cancer, and relapsed or refractory B-cell non-Hodgkin lymphoma, highlighting the efficacy, safety, and innovative approaches that involve combining evorpacept with established treatments. ALX Oncology Holdings Inc. has garnered attention in the field of immuno-oncology with its investigational therapy, evorpacept, aimed at inhibiting the CD47 immune checkpoint pathway. With a focus ...
ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder CancerSOUTH SAN FRANCISCO, Calif., June 02, 2024 - ALX Oncology Holdings Inc. (ALX Oncology), a leading immuno-oncology company focused on developing therapies that target the CD47 immune checkpoint pathway, unveiled promising data from its Phase 1 ASPEN-07 clinical trial at the 2024 American Society of Cancer Oncology (ASCO) Annual Meeting in Chicago. This study explored the combination of ALX Oncology s drug, Evorpacept, with the antibody-drug conjugate (ADC) PADCEV (enfortumab vedotin) in patients suffering from advanced bladder cancer.The ASPEN-07 ...
ALX Oncology Holdings Inc s Evorpacept, a novel therapeutic candidate for the treatment of cancer, has achieved significant progress with the acceptance of two clinical abstracts for presentation at the upcoming AACR Annual Meeting. One of the abstracts highlights an investigator-initiated trial involving patients with relapsed or refractory B-cell non-Hodgkin lymphoma, which has been selected for oral presentation. Moreover, Alx Oncology Holdings Inc experienced revenue growth during the same period, showcasing the company s potential in the biopharmaceutical industry.Facts:1. ALX Oncology Holdings Inc s Evorpacept has achieved two abstract acceptances for presentation at the AACR Annual Meeting.2. The firs...
Alx Oncology Holdings Inc’s Comment on Sales, Marketing and Customers
The company currently has no products on the market but expects its operations to be governed by various U.S. federal and state healthcare laws and regulations. Its customers include healthcare providers, prescribers, consultants, third-party payors, physicians, and other parties involved in the recommendation, prescription, marketing, sale, and distribution of its products. The company may also be subject to patient data privacy and security regulations, as well as additional healthcare statutory and regulatory requirements in foreign jurisdictions where it operates.
Sources:
Alx Oncology Holdings Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Alx Oncology Holdings Inc’s corporate clients.
For your research, we’ve provided 9 tables on Alx Oncology Holdings Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
